Compatibility of a live infectious bovine rhinotraheitis (IBR) marker vaccine and an inactivated bovine viral diarrhoea virus (BVDV) vaccine

Vaccine

Volumn 25, Issue 36, 2007, Pages 6613-6617

  Alvarez M ^a   Bielsa, J Muñoz ^b   Santos, L ^c   Makoschey, B ^b  

^a UNIVERSITY OF LEÓN   (Spain)

^b INTERVET INTERNATIONAL BV   (Netherlands)

^c Intervet Laboratories SA   (Spain)

Author keywords

Cattle; Compatibility; Herpesvirus; Marker vaccine; Pestivirus

Indexed keywords

BOVILIS; INACTIVATED BOVINE VIRAL DIARRHEA VIRUS VACCINE; INACTIVATED VACCINE; LIVE INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE; LIVE VACCINE; MARKER VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CATTLE PLAGUE VIRUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEIFER; INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; DIARRHEA VIRUSES, BOVINE VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFECTIOUS BOVINE RHINOTRACHEITIS; TIME FACTORS; VACCINATION; VACCINES, INACTIVATED; VACCINES, MARKER; VIRAL VACCINES;

EID: 34547676669     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.050     Document Type: Article

References (12)

1. Bätza H.J. The new BHV-1 regulation. Berl Münch Tierärztl Wochenschr 116 (2003) 179-182
2. Moennig V., Houe H., and Lindberg A. BVD control in Europe: current status and perspectives. Anim Health Res Rev 6 (2005) 63-74
3. Kaashoek M.J., Moerman A., Madic J., Rijsewijk F.A., Quak J., Gielkens A.L., et al. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine 12 (1994) 439-444
4. Thursfield M. Veterinary epidemiology. 2nd ed. (1995), Blackwell Science Ltd., Oxford, United Kingdom pp. 268-269
5. Graham D.A., German A., Mawhinney K.A., and Goodall E.A. Antibody responses of naive cattle to two inactivated bovine viral diarrhoea virus vaccines, measured by indirect and blocking ELISA's and virus neutralisation. Vet Rec 152 (2003) 795-800
6. Makoschey B., Sonnemans D., Muñoz Bielsa J., Franken P., Mars M.H., Santos L., et al. Evaluation of the induction of NS3 specific BVDV antibodies using a commercial inactivated BVDV vaccine in immunisation and challenge trials. Vaccine 25 (2007) 6140-6145
7. Patel J.R., Didlick S., and Brunner R. Untersuchungen mit einem IBR-Marker-Lebendimpfstoff zum Nachweis eines vereinfachten Impfschemas (Grundimmunisierung durch Einmalimpfung). Tierärztl Umsch 59 (2004) 583-586
8. Makoschey B., and Beer M. Assessment of the risk of transmission of vaccine viruses by using insufficiently cleaned injection devices. Vet Rec 155 (2004) 563-564
9. Babiuk L.A., Drunen Littel-van den Hurk Sv, and Tikoo S.K. Immunology of bovine herpesvirus 1 infection. Vet Microbiol 53 (1996) 31-42
10. Bolin S.R., and Ridpath J.F. Assesment of protection from systemic infection or disease afforded by low to intermediate titres of passively acquired neutralising antibodies against bovine viral diarrhoea virus in calves. Am J Vet Res 56 (1995) 755-759
11. Bielefeldt O.H., and Babiuk L.A. Viral-bacterial pneumonia in calves: effect of bovine herpesvirus-1 on immunologic functions. J Infect Dis 151 (1985) 937-947
12. Makoschey B., Chanter N., and Reddick D.A. Comprehensive protection against all important primary pathogens within the bovine respiratory disease complex by combination of two vaccines. Der Praktische Tierarzt 87 (2006) 819-826